Pembrolizumab with axitinib for untreated advanced renal cell carcinoma

  • Technology appraisal guidance
  • TA650
  • Published: 

Register as a stakeholder

Evidence

Documents containing the evidence that was used to develop the recommendations.

Supporting evidence